Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date: IgA Nephropathy (IgAN) Program: First dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses including: selective lowering of only the disease-causing galactose-deficient IgA1 (Gd-IgA1) while sparing off-target effects on healthy antibodies (IgA, IgM, IgE, IgG), resolution of blood in the …

Optimism about its growing AI business gave the Google parent entry to a rarefied club.

The active ETF market split along strategy lines in 2025, with discretionary equity funds gaining 3.3% market share while systematic equity funds lost 1.1%, according to Morningstar data shared by Ben Johnson, head of client solutions and asset management at the firm. The divergence shows not all active strategies performed equally, with the T.

RADNOR, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.

Meta on Monday appointed banker Dina Powell McCormick as president and vice chairman, tapping a former member of the Trump administration to help steer the technology giant's massive AI infrastructure expansion.

Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment.

It's a bird. It's a plane.

Franklin Covey Co. remains a Buy despite recent underperformance, with the market overlooking deferred revenue growth and sales strategy improvements. FC's transition to a split sales team and focus on new logos is driving a 25% increase in new client invoicing and higher service attach rates. Deferred revenue and multiyear contract metrics signal increasing customer stickiness, even as short-term margins and cash flow remain pressured.

Investors need to pay close attention to Holley stock based on the movements in the options market lately.

HD is gearing up for a 2026 housing rebound with Pro-focused tools and supply-chain upgrades to scale fast.

Zuckerberg spoke about the need for more “masculine energy” in corporate America, which he said had become “culturally neutered” in an episode of Joe Rogan's podcast last year—comments that were widely seen as targeting inclusivity initiatives by former Chief Operating Officer Sheryl Sandberg. “I think having a culture that celebrates the aggression a bit more has its own merits that are really positive,” he said.

Paramount said Monday it would push forward with its hostile bid for Warner Bros. Discovery by nominating directors to the WBD board that would engage with Paramount's offer, while also filing a lawsuit against the company to force it to disclose information about Netflix's offer.

CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases.2 The SPINRAZA European Union marketing authorization has been updated to include the high dose regimen. The new high dose regimen comprises a more rapid loading phase, two 50 mg loading doses …

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, announced it has been recognized as a Leader in five quadrants in the ISG Provider Lens™ Insurance Services 2025 report. These include both service specialist capabilities, Life & Retirement and Property & Casualty, as well as the newly introduced categories for GenAI, Agentic AI and Global Capability Centers. This strong positioning highlights EXL's broad, end-to-end impact across the insurance value chain and its ability to apply next-generation intelligence at scale.

WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.

CrowdStrike agrees to acquire SGNL to boost identity security for AI-driven enterprises, adding real-time, risk-based access controls to the Falcon platform.

HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.

Ampco-Pittsburgh's upgrade to Outperform reflects tariff pass-throughs, strategic exits, and ALP-driven growth at undervalued levels.

Thryv Holdings is a compelling small-cap value play, transitioning from Yellow Pages to a recurring SaaS business with >30% SaaS growth. THRY's SaaS segment now comprises 58% of revenue, with organic growth at 14% and adjusted EBITDA margin near 20%. Despite a 60% stock decline, THRY trades at just 3.3x EV/FY25 adjusted EBITDA, offering deep value amid market pessimism.